...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1-or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the US Food and Drug Administration (FDA)
【24h】

Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R/R) Isocitrate Dehydrogenase (IDH)1-or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the US Food and Drug Administration (FDA)

机译:用伊昔透核(IVO)和enaSidenib(ena)分化综合征的发病率用于治疗复发或难治性(R / R)异柠檬酸脱氢酶(IDH)1-或IDH2-突变的急性髓性白血病(AML)的患者:由此进行系统分析 美国食品和药物管理局(FDA)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号